Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics. The company's lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, enabling the discovery of first- and best-in-class therapies with the potential to benefit broader patient populations.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/28/26	$21,000,000	Series A	Elikon Venture InnoPinnacle Fund Mitsubishi UFJ Capital Root Ventures UTokyo IPC Vision Incubate Co.	undisclosed